Approval · Notice of Compliance 30635 · 2023
NAT-LENALIDOMIDE: Notice of Compliance 30635
Issued May 3, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30635
- Date
- May 3, 2023
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to The Product Monograph. Update to Labels. Update to the Package Insert
- Canadian reference product
- REVLIMID
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-LENALIDOMIDE | Not yet assigned | — |
Medicinal ingredients
- LENALIDOMIDE 2.5 MG per CAP
- LENALIDOMIDE 5 MG per CAP
- LENALIDOMIDE 7.5 MG per CAP
- LENALIDOMIDE 10 MG per CAP
- LENALIDOMIDE 15 MG per CAP
- LENALIDOMIDE 20 MG per CAP
- LENALIDOMIDE 25 MG per CAP